Search

The article discusses whether a specific nasal spray should be classified as a medical device or as a medicinal product. According to the Supreme Court, this nasal spray, which primarily acts physically and neutralizes viruses before they affect the mucous membrane, is not considered a medicinal product. The misleading of a product is only examined based on specific claims. The appellate court classified the nasal spray as a medical device because it has a physical effect and neutralizes viruses before they attack the mucous membrane. The plaintiff argued that the product should be classified as a medicinal product and contains misleading statements. The Supreme Court confirmed the appellate court's decision and referred to a decision of the German Federal Administrative Court. The question of whether it is a presentation medicinal product was no longer relevant in the appeal process. [Extracted from the article]

Background: Postdural puncture headache (PDPH) occurs in up to 11% of patients after spinal anesthesia and in more than 80% after dural perforation upon epidural anesthesia. It represents a severe anesthesiological complication in obstetric patients. If conservative medication measures do not result in a timely relief of symptoms, the current guidelines recommend the early implementation of an epidural blood patch; however, although performing an epidural blood patch is effective to treat PDPH, potential side effects include neurological complications, spinal hematoma and infections. Assumed to reduce cerebral vasodilatation as a potential pathophysiological driver of PDPH, the transnasal block of the sphenopalatine ganglion with local anesthetics is discussed as an alternative approach.Methods: In this case study a modification of this technique is reported using a mucosal atomization device (MAD) for off-label nasal administration of lidocaine in two obstetric patients suffering from PDPH. Up to now there is no experience with this modified technique in obstetric anesthesiology.Results: The first patient (25-year-old secundigravida, body mass index [BMI] 54.7 kg/m2) displayed a pronounced PDPH with nausea and vomiting during the first day after a cesarean section under spinal anesthesia (3 attempts). The second patient (32-year-old tertiagravida, BMI 27.3 kg/m2) was readmitted to hospital due to PDPH 4 days after a natural birth under epidural anesthesia. Whereas conservative measures and therapeutic attempts with nonopioid analgesics and caffeine did not result in a sufficient treatment success, intranasal lidocaine administration via a MAD led to an immediate and persisting symptom relief. Both patients could be discharged from hospital after 24 h of surveillance and did not report any relevant side effects of the lidocaine administration.Conclusion: The described noninvasive and simple procedure represents a valuable addition to previously known treatment options for PDPH and a potential alternative to an epidural blood patch in obstetric patients with PDPH. Prospective studies are needed to validate the findings. [ABSTRACT FROM AUTHOR]

The article discusses the court case OVG NRW, ruling v. September 26, 2019-13A 3290/17, n.rkr., Revision pending at the BVerwG under ref. 3C19.19 (VG Cologne - 7K6236 / 14) wherein claim for nasal spray as presentation drug against runny nose. It points out to therapeutic effectiveness of the products, requirements of a pharmaceutical presentation and pharmacology.

The assumption that the human brain is an insulin-independent organ was disproved with the discovery of insulin receptors in the central nervous system in the year 1978. Evidence has been provided for a high density of insulin receptors in brain regions responsible for cognitive memory processes (hippocampus) and for the regulation of appetite (hypothalamus). Accordingly, in animal studies an increased insulin level in the central nervous system leads to an improvement of hippocampal memory function and a decrease of food intake. Similar results were obtained in humans using the method of intranasal administration of insulin. Intranasal insulin reaches the brain and the cerebrospinal fluid via the olfactory epithelium and olfactory nerve fiber bundles leading through the lamina cribrosa to the olfactory bulb. Thus, this method renders the investigation of specific insulin effects in humans possible. The therapeutic potential of an intranasal insulin administration for the treatment of diseases for which an imbalance of the central nervous insulin metabolism is discussed (e.g. Alzheimer's disease, diabetes mellitus and obesity) can only be estimated with the help of further clinical studies. [ABSTRACT FROM AUTHOR]